1
Three endpoints were analyzed: disease- free interval, time to Stage III metastasis, and survival.
2
There was a trend for a longer disease- free interval after M-ILP.
3
The overall survival rate, responses, disease- free interval and toxicities were assessed.
4
There was a drug- free interval of one week between the two therapy phases.
5
Progestins are most effective in women with well-differentiated tumours and long disease- free interval.
6
The primary end point was prolongation of a relapse- free interval.
7
Furthermore, the recurrence- free interval in the scoliosis group was short.
8
The median duration of chemotherapy- free interval for patients with recurrent disease was 7 months.
9
Patients in the first treatment- free interval had relatively high scores.
10
Progestins are most effective in women with well-differentiated tumours and a long disease- free interval.
11
Conclusion: The Sistrunk procedure is the gold standard technique with the highest recurrence- free interval rate.
12
Factors that did not influence prognosis were: disease free interval, location and number of metastases.
13
Primary end points were overall survival and disease- free interval.
14
Ablation of sarcoma metastases may improve patient quality of life by extending the chemotherapy- free interval.
15
We did not identify significant differences in disease- free interval.
16
Surprisingly, none of the grading methods was effective in predicting nodal spread or progression- free interval.
